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We enrolled 30 patients on a prospective phase II trial utilizing a total body irradiation (TBI)ebased myeloa-
blative preparative regimen (ﬂudarabine 30 mg/m2/day  3 days and TBI 150 cGy twice per day on day -4 to -1
[total dose 1200 cGy]) followed by infusion of unmanipulated peripheral blood stem cells from a haploidentical
family donor (haplo). Postgrafting immunosuppression consisted of cyclophosphamide 50 mg/kg/day on days 3
and 4, mycophenolate mofetil through day 35, and tacrolimus through day 180. Median patient age was 46.5
years (range, 24 to 60). Transplantation diagnosis included acute myelogenous leukemia (n ¼ 16), acute
lymphoblastic leukemia (n¼ 6), chronic myelogenous leukemia (n¼ 5), myelodysplastic syndrome (n ¼ 1), and
non-Hodgkin’s lymphoma (n¼ 2). Using the Dana Farber/Center for International Blood andMarrow Transplant
Research/Disease Risk Index (DRI), patients were classiﬁed as low (n ¼ 4), intermediate (n ¼ 12), high (n ¼ 11),
and very high (n ¼ 3) risk. All patients engrafted with a median time to neutrophil and platelet recovery of 16
and 25 days, respectively. All evaluable patients achieved sustained complete donor T cell and myeloid
chimerism by day þ30. Acute graft-versus-host disease (GVHD) grades II to IV and III and IV was seen in 43%
and 23%, respectively. The cumulative incidence of chronic GVHD was 56% (severe in 10%). After a median
follow-up of 24 months, the estimated 2-year overall survival (OS), disease-free survival (DFS), nonrelapse
mortality, and relapse rate were 78%, 73%, 3%, and 24%, respectively. Two-year DFS and relapse rate in patients
with low/intermediate risk disease was 100% and 0%, respectively, compared with 39% and 53% for patients
with high/very high risk disease. When compared with a contemporaneously treated cohort of patients at our
institution receiving myeloablative HLA-matched unrelated donor (MUD) transplantation (acute myelogenous
leukemia [n ¼ 17], acute lymphoblastic leukemia [n ¼ 15], chronic myelogenous leukemia [n ¼ 7], myelo-
dysplastic syndrome [n ¼ 7], non-Hodgkin lymphoma [n ¼ 1], chronic lymphoblastic leukemia [n ¼ 1]),
outcomes were statistically similar, with 2-yr OS and DFS being 78% and 73%, respectively after haplo trans-
plantation versus 71% and 64%, respectively, after MUD transplantation. In patients with DRI low/intermediate
risk disease, 2-yr DFS was superior after haplo compared with MUD transplantations (100% versus 74%,
P ¼ .032), whereas there was no difference in DFS in patients with high/very high risk disease (39% versus 37%
for haplo and MUD respectively, P ¼ .821). Grade II to IV acute GVHD was seen less often after haplo compared
with MUD transplantation (43% versus 63%, P ¼ .049), as was moderate-to-severe chronic GVHD (22% versus
58%, P ¼ .003). Myeloablative haplo transplantation using this regimen is a valid option for patients with
advanced hematologic malignancies who lack timely access to a conventional donor. Outcomes appear at least
equivalent to those seen in contemporaneous patients who underwent transplantation from MUD.
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ty for Blood and Marrow Transplantation.INTRODUCTION
Seventy percent of patients who urgently need a
hematopoietic cell transplant (HSCT) do not have an avail-
able HLA-matched sibling donor. In such patients, a search
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8/8 HLA-identical donor for approximately 30% to 40% of
transplant recipients. The probability of ﬁnding an accept-
able MUD varies by racial/ethnic groups, ranging from 75% in
white Europeans, to 30% to 40% in Mexican and Central/
South Americans, to 15% to 20% for African Americans and
black Caribbeans [1]. In addition, MUD transplantation is also
complicated by the amount of time it takes from search
initiation to transplantation, causing some patients to
relapse or physically deteriorate while waiting for trans-
plantation. In contrast, a haploidentical family member
(haplo) can be identiﬁed and rapidly utilized in nearly all
cases.
Historically, HSCT from partially HLA-mismatched rela-
tive has been complicated by unacceptably high incidences
of graft rejection, severe graft-versus-host disease (GVHD),
and nonrelapse mortality (NRM) [2,3]. To address the risk of
graft rejection and GVHD, extensive T cell depletion has been
utilized in association with antithymocyte globulin (ATG)
and high peripheral blood stem cell (PBSC) dose [4]; how-
ever, NRM from infectious complications remains a chal-
lenge. More recently, the investigators at Johns Hopkins
University have pioneered a method to selectively deplete
alloreactive cells in vivo by administering high doses of
cyclophosphamide (Cy) in a narrow window after trans-
plantation [5]. After nonmyeloablative (NMA) conditioning,
this approach has resulted in lowNRM (4% and 15% at 1 and 2
years, respectively), because of low rates of GVHD and in-
fectious complications. Immune reconstitution was prom-
ising with low risk of cytomegalovirus (CMV) or invasive
mold infections. Using high-dose, post-transplantation
cyclophosphamide (PT/Cy), crossing the HLA barrier in HSCT
is now feasible without the need for extensive T cell deple-
tion or serotherapy.
Although NMA haplo-HSCT utilizing PT/Cy results in low
rates of GVHD, infection, and NRM, relapse remains the
predominant cause of treatment failure, occurring in
approximately 45% to 51% of patients [5,6]. To reduce the risk
of relapse often associated with the use of NMA preparative
regimens, our group and others have demonstrated the
feasibility of myeloablative T cellereplete haplo-HSCT uti-
lizing PT/Cy [7-9]. We have previously demonstrated that
after a busulfan-based myeloablative haplo-HSCT, outcomes
were promising with a 1-year estimate of overall survival
(OS), disease-free survival (DFS), relapse, and NRM of 69%,
50%, 40%, and 10%, respectively, for all patients, and 88%, 67%,
33%, and 0% respectively for standard-risk patients (acute
leukemia in remission or chronic-phase chronic myeloge-
nous leukemia) [9]. An unexpected ﬁnding in that study was
a high incidence of hemorrhagic cystitis (HC), and we hy-
pothesized that the replacement of total body irradiation
(TBI) for busulfan in the conditioning regimen would
decrease the incidence of HC without affecting the overall
safety and efﬁcacy of the procedure.
PATIENTS AND METHODS
Eligibility and Enrollment
Thirty patients were accrued to this prospective study.Written informed
consent was obtained for all of the patients in accordance with the Decla-
ration of Helsinki. The study was approved by the institutional review board
at Northside Hospital. Patients were eligible for inclusion if they were be-
tween 18 and 60 years of age, had a high-risk hematologic malignancy, were
without a readily available matched related or unrelated donor, and had
adequate organ function as deﬁned by bilirubin <2.5 mg/dL, creatinine <2
mg/dL, cardiac ejection fraction45%, forced expiratory volume in 1 second
and forced vital capacity 60% predicted, Karnofsky performance status
70%, and were human immunodeﬁciency virus negative. Donors wererequired to be ﬁrst-degree relatives (parent, child, sibling) of the recipient
and partially HLAmatched at 5 of 10 to 8 of 10 loci with the recipient. Donors
were excluded if they had a positive HLA crossmatch in the host-versus-
graft direction or high titer donor-speciﬁc antibodies, as determined by
the pretransplantation panel reactive antibody testing.
Treatment Plan
Transplantation conditioning consisted of ﬂudarabine 30 mg/m2/day on
days -7 to -5 and TBI 150 cGy twice daily on days -4 to -1 (total dose 1200
cGy). On day 0, patients received an unmanipulated PBSC allograft with a
CD34 dose capped at 5  106/kg recipient weight (our institutional
standard-of-care for all allogeneic transplantation protocols, based on his-
torical data showing a correlation between CD34 dose and chronic GVHD
[10,11]). On days þ3 and þ4, patients received 2 doses of Cy 50 mg/kg/day
with mesna. Post-transplantation immunosuppression was initiated on
day þ5 with intravenous tacrolimus (target level 5 to 15 ng/mL) and oral
mycophenolate mofetil (MMF) (15 mg/kg 3 times daily with a maximum
daily dose of 3 gm). No immunosuppressive agents were administered until
24 hours after the last dose of PT/Cy, including corticosteroids. MMF and
tacrolimus were discontinued without taper at day þ35 and þ180, respec-
tively, in the absence of GVHD.
Antimicrobial prophylaxis was administered according to institutional
practice guidelines. Standard prophylaxis was started on day 0 including a
quinolone antibiotic and acyclovir. Antifungal prophylaxis consisted of an
echinocandin (caspofungin or micafungin) until day þ5, when the patient
was started on oral therapy with either voriconazole or posaconazole. Fil-
grastim 5 mg/kg was given daily starting day þ5 and continuing until
neutrophil engraftment. Standard pneumocystis prophylaxis was started on
day þ30 and continued at least 6 months after transplantation and until
immunosuppression was discontinued. Quantitative CMV PCR was moni-
tored weekly starting day þ1 and pre-emptive therapy was initiated if viral
reactivation was detected (400 copies/mL). Quinolone antibiotic was
continued until day þ100 for BK virus prophylaxis.
Study Endpoints
Neutrophil engraftment was deﬁned as the ﬁrst of 3 days of an absolute
neutrophil count of >.5  109/L after transplantation. Platelet engraftment
was deﬁned as a platelet count of >20,000/mL without transfusion for the 7
preceding days. Acute GVHD was scored based on the modiﬁed Keystone
criteria [12]. Grades III and IV acute GVHD was termed severe acute GVHD.
Chronic GVHD diagnosis and grading were based on the National Institutes
of Health consensus criteria [13]. BK virus HCwas deﬁned by the presence of
urinary symptoms/signs in association with BK viruria. BKV-HC was classi-
ﬁed according to the to the NCI Common Terminology Criteria for Adverse
Events version 4.0: grade II, frequency with moderate dysuria and/or
macroscopic hematuria; grade III, hospitalization indicated for transfusion,
i.v. pain medications, and bladder irrigation; and grade IV, catastrophic
bleeding; major nonelective intervention indicated. Severe BK virus HC was
deﬁned as grade  III. Patient outcomes are reported as of January 1, 2015.
The major study endpoints were sustained donor engraftment, incidence
and severity of GVHD, NRM, DFS, and OS. Patients were considered to have
died of NRM if there was no evidence of disease relapse or progression
before death.
Chimerism Analysis
We assessed donor-recipient chimerism by the PCR-based ampliﬁcation
of a polymorphic short tandem repeat regions, followed by fragment sep-
aration by high resolution capillary electrophoresis (ABI 3130 XL Genetic
Analyzer, Life Technologies, Carlsbad, CA) and quantitation using Gene-
Mapper Software (Life Technologies). Peripheral blood samples were
collected for chimerism analysis on days 30, 60, and 90 after transplantation.
Samples were separated into myeloid and T cell lymphoid fractions by
indirect sorting with immunomagnetic beads (StemCell Technologies,
Vancouver, British Columbia, Canada). Primary antibodies were speciﬁc to
CD33 and CD66b for myeloid cell and to CD3 for lymphoid T cell fraction-
ation, respectively. The quality of sort was assessed using multiparametric
ﬂow cytometry (FACSCanto cytometer, DIVA analysis software; BD Bio-
Sciences, San Jose, CA). Genomic DNA was extracted from immunosorted
cells and multiplex PCR was performed using commercial ﬂuorescently
labeled primer sets (ProﬁlerPlus, COﬁler, NGM kits; Life Technologies). Four
or 5-color ﬂuorescence detection was performed on ABI 3130xl Genetic
Analyzer and quantiﬁed using GeneMapper Software. For each informative
short tandem repeat loci, allelic peak heights were determined, and the
percentage of host alleles calculated as (S[host alleles peak height])/
(S[host þ donor alleles peak heights]) * 100. The range of the error of
chimerism was determined to be nonuniform between different levels of
chimerism and did not exceed 3.23%, 6.66%, 8.33%, 8.89%, 8.60%, 5.31%, and
3.07% for 1% to 5%, 6% to 20%, 21% to 40%, 41% to 60%, 61% to 80%, 81% to 95%,
Table 1
Patient and Transplantation Characteristics
Characteristic Value
Patients (n ¼ 30)
Age, median (range), yr
Patient 46 (24-60)
Donor 32 (18-65)
HLA match
GVH
5/10 18
6/10 8
7/10 4
8/10 0
HVG
5/10 13
6/10 12
7/10 3
8/10 2
Donor/recipient gender
Male/female 8
Female/female 8
Male/male 10
Female/male 4
Donor relationship
Parent 2
Sibling 12
Child 16
Transplanted cell dose, median (range)
CD34 ( 106/kg) 5.01 (4.01-5.06)
CD3 ( 107/kg) 15.56 (3.74-53.8)
Disease
AML 16
CR1 7
CR2/3 7
PIF 2
ALL 6
CR1 4
CR2 1
PIF 1
CML 5
CP 2
AP/BC 3
MDS 1
NHL 2
Disease risk (DFDRI)
Very high 3
High 11
Intermediate 12
Low 4
HCT-CI
0 7
1-2 13
3-5 10
GVH indicates graft-versus-host direction; HVG, host-versus-graft direc-
tion; AML, acute myelogenous leukemia; CR, complete remission; PIF, pri-
mary induction failure; ALL, acute lymphoblastic leukemia; CML, chronic
myelogenous leukemia; CP, chronic phase; AP, accelerated phase; BC, blast
crisis; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma;
DFDRI, Dana Farber disease risk index; HCT-CI, hematopoietic cell trans-
plantation comorbidity index.
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were selected empirically in our laboratory.
Comparison to Contemporaneous Cohort of Myeloablative Matched
Unrelated Donor Transplantation Patients
A contemporaneous group of transplant recipients receiving myeloa-
blative conditioning followed by MUD transplantation were utilized as a
comparator cohort. Forty-eight consecutive patients receiving a myeloa-
blative T cellereplete MUD transplant were analyzed. All donor-recipient
pairs were HLA matched at 8/8 alleles (HLA-A, -B, -C, and -DR).
Statistical Analysis
The patient characteristics were compared between haplo and MUD
transplantation groups using theWilcoxon rank-sum test for the continuous
variables and Fisher’s exact test for the categorical variables. The OS and DFS
were estimated by the Kaplan-Meier method. Comparisons of OS and DFS
between different transplantations were evaluated using the log-rank test.
The cumulative incidences, accounting for competing risks, were estimated
for NRM, relapse, GVHD and BK cystitis. NRM and relapse were competing
risks and they were taken together to deﬁne DFS. In the competing risks
models of GVHD (or BK cystitis), death without GVHD (or death without BK
cystitis) was deﬁned as a competing risk. The cumulative incidences of these
endpoints were compared between different transplantations using the
Gray’s test. All P values were 2-sided and P values less than .05 were
considered as signiﬁcant.
RESULTS
Characteristics of the Study Cohort
A total of 30 patients with a median age of 46.5 years
(range, 24 to 60) with high risk hematologic malignancies
were enrolled between April 2012 andMay 2014. Patient and
donor characteristics are listed in Table 1. Transplantation
diagnosis included acute myelogenous leukemia (n ¼ 16),
acute lymphoblastic leukemia (n ¼ 6), chronic myelogenous
leukemia (n ¼ 5), myelodysplastic syndrome (n ¼ 1), and
non-Hodgkin lymphoma (n ¼ 2). Using the recently pub-
lished Dana Farber/Center for International Blood and
Marrow Transplant Research disease risk index (DRI) [14],
patients were classiﬁed as low (n¼ 4), intermediate (n¼ 12),
high (n ¼ 11), and very high (n ¼ 3) risk. Donor-recipient
pairs were matched at a median of 5 (out of 10) HLA loci in
the graft-versus-host direction (range, 5 to 7) and a median
of 6 (out of 10) HLA loci in the host-versus-graft direction
(range, 5 to 8). No patients had donor-speciﬁc antibodies
before transplantation.
Engraftment and Chimerism
Therewere no cases of primary or secondary engraftment
failure. Median times to neutrophil and platelet recovery
were 16 and 25 days, respectively. Achievement of full donor
chimerism was rapid, with all evaluable patients achieving
durable complete (>95%) donor T cell and myeloid chime-
rism by day þ30.
GVHD and NRM
The cumulative incidences of grades II to IV and grades III
and IV acute GVHD were 43% and 23%, respectively. The cu-
mulative incidences of any, moderate-to-severe, and severe
chronic GVHD were 56%, 22%, and 10% respectively
(Figure 1). Of the 16 patients who developed chronic GVHD,
National Institutes of Health severity grade was mild, mod-
erate, and severe in 10, 3, and 3 patients, respectively. Sys-
temic immunosuppression was required for treatment in all
patients with moderate/severe chronic GVHD and in 4 of 10
patients with mild chronic GVHD. When considering the 22
patients who were alive and in remission 1 year after
transplantation (of the 28 evaluable patients with sufﬁcient
follow-up), only 5 of 22 patients required continued systemic
immunosuppression past 1 year after transplantation. NRMat 2 years was 3%, which consisted of 1 death from nonin-
fectious respiratory failure/acute respiratory distress syn-
drome 8 months after transplantation in a patient with
chronic GVHD.Regimen-related Toxicity and Infectious Complications
As noted in our prior experience with busulfan-based
myeloablative haplo-HSCT, post-transplantation fever was
common and occurred in the ﬁrst 5 post-transplantation
days in all patients. In 23 of 30 patients, no infectious cause
was found for the fever, whereas an infectious source was
noted in 7 patients (gram-positive bacteremia [n ¼ 6],
Figure 2. Cumulative incidence of (A) hemorrhagic cystitis of any grade and
(B) grade  3 hemorrhagic cystitis.
Figure 1. Cumulative incidence of (A) acute GVHD and (B) chronic GVHD.
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after administration of PT/Cy. CMV reactivation (400
copies/mL) occurred in 15 of 26 (58%) of at-risk patients
(either donor and/or recipient with CMV-positive serostatus)
at a median of day þ43 after transplantation (range, 11 to
157) and was treated pre-emptively as per institutional
guidelines. CMV disease did not occur. There were no epi-
sodes of invasive mold infection or infectious death in the
ﬁrst 100 days after transplantation. There were no cases of
Epstein-Barr virus reactivation.
BK viruseassociated HC of any grade occurred in 30% of
patients and was severe (grade 3) in 7%. The median post-
transplantation day for developing cystitis was day 31
(range, 7 to 108). Compared with our previous experience
with busulfan-based myeloablative haplo-HSCT [9], HC
occurred signiﬁcantly less often after TBI-based myeloa-
blative haplo-HSCT (any grade: 30% versus 75%, P ¼ .005;
severe HC: 7% versus 30%, P ¼ .037) (Figure 2).Relapse, DFS, and OS
With a median follow-up of 24 months (range, 8 to 44
months), estimated 2-year OS, DFS, and relapse was 78%,
73%, and 24%, respectively for all patients; 100%, 100%, and
0%, respectively, for patients with low/intermediate disease
risk; 52%, 39%, and 53% for patients with high/very high
disease risk (Figure 3). Twenty-four patients remain alive
and 22 of these remain disease-free. Five of 6 deaths on study
were attributable to disease relapse/progression.Comparison of Transplantation Outcomes Between
Myeloablative Haplo Versus MUD Transplantation
We compared outcomes of patients on this study
receiving myeloablative haplo transplantation with a
contemporaneously treated cohort of consecutive patients at
our institution receiving myeloablative T cellereplete MUD
transplantation. MUD donor-recipient pairs were HLA
matched at 10/10 loci in 94% and 9/10 (single HLA-DQ
mismatch) in 6%. Conditioning regimens for MUD trans-
plantations included TBI/Cy (n ¼ 4), TBI/etoposide (VP16)
(n ¼ 10), busulfan/cyclophosphamide (Bu/Cy) (n ¼ 31), and
ﬂudarabine/busulfan for 4 days (Flu/Bu4) (n ¼ 3). Hap-
loidentical and MUD transplantation patients were well
matched according to age, diagnosis, disease risk, CMV
serostatus and comorbidity index, both when considering
the entire MUD cohort or the subset of MUD patients
receiving PBSC (Table 2). The groups did differ in the use of
PBSC as the stem cell source, which was utilized in all 30
haploidentical transplant recipients compared with 32 of 48
MUD transplant recipients (100% versus 67%, P< .001). GVHD
prophylaxis was tacrolimus and methotrexate in all MUD
patients, and no patients received serotherapy.
When compared with the outcomes for recipients of
myeloablative MUD transplantation, outcomes after mye-
loablative haplo-HSCT were statistically similar with 2-yr OS
and DFS of 78% and 73%, respectively, after haplo trans-
plantation versus 71% and 64%, respectively, after MUD
transplantation (Figure 4A). In patients with DRI low/inter-
mediate risk disease, 2-yr DFS was superior after
Figure 3. Kaplan-Meier analysis of overall survival, disease-free survival,
nonrelapse mortality and relapse for (A) all patients, (B) patients with low/
intermediate disease risk, and (C) patients with high/very high disease risk.
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74%, P¼ .032) (Figure 4B), whereas therewas no difference in
DFS in patients with high/very high risk disease (39% versus
37% for haplo and MUD, respectively, P ¼ .821) (Figure 4C).
Grade II to IV acute GVHD was seen less often after haplo
compared with after MUD transplantation (43% versus 63%,
P ¼ .049), as was moderate-to-severe chronic GVHD (22%
versus 58%, P¼ .003) (Figure 5). WhenMUD transplantations
were restricted to the 32 patients receiving PBSC as the stem
cell source, similar trends were seen (Table 3).DISCUSSION
We report the outcomes of a prospective study of a TBI-
based myeloablative, T cellereplete haploidentical PBSCtransplantation. All patients engrafted and demonstrated
100% donor T cell and myeloid chimerism by day þ30. The 2-
year NRM and OS was 3% and 78%, respectively, for all pa-
tients, and 0% and 100%, respectively, for patients with low/
intermediate disease risk. The cumulative incidence of grade
III and IV acute GVHD andmoderate-to-severe chronic GVHD
was 23% and 22%, which are similar to those expected with
myeloablative PBSC transplantations from HLA-matched
donors. Remarkably, for a study of myeloablative trans-
plantation from haploidentical donors, serious infections
were rare. Notably, there were no serious CMV and invasive
mold infections and no infectious mortality. BK
viruseassociated cystitis, which was a major cause of
morbidity in our previously reported experience with
busulfan-based myeloablative haploidentical trans-
plantation [9], was signiﬁcantly less frequent after TBI-based
myeloablative conditioning with clinically signiﬁcant (grade
 3) HC occurring in only 2 (7%) patients.
In the past decade, there has been a growing interest in
the use of haplo-HSCT because of the rapid and nearly uni-
versal availability of donors, which is a critical issue in pa-
tients with advanced hematologic malignancies. Enthusiasm
for this approach has been furthered by signiﬁcant advances
in the ﬁeld and improvements in supportive care, which have
increased the safety of providing transplantations for pa-
tients across HLA barriers bymitigating the risks of infection,
graft failure, and GVHD. A major advance in the success of
haplo-HSCT is the use of properly timed PT/Cy, a technique
pioneered by investigators at Johns Hopkins University
[5,15]. In this strategy, patients receive an unmanipulated
bone marrow (BM) allograft after an NMA conditioning
regimen consisting of ﬂudarabine, low-dose TBI (200 cGy),
and Cy. After PT/Cy, patients receive GVHD prophylaxis
consisting of tacrolimus and MMF, which results in accept-
ably low rates of graft rejection and GVHD, the 2 major his-
torical barriers to successful haplo-HSCT. Furthermore, there
was effective clinical immune reconstitution as demon-
strated by the low incidence of severe opportunistic in-
fections. However, relapse represented the major cause of
treatment failure, occurring in 45% to 51% of transplant re-
cipients [5,6]. One explanation for the high rate of relapse, as
in other NMA HSCT trials, is that the transplantation condi-
tioning was not intense enough to achieve sufﬁcient tumor
cytoreduction [16-19].
To reduce the risk of relapse in patients with high risk
hematologic malignancies, our group has previously re-
ported on the results of myeloablative haploidentical PBSCT,
utilizing a busulfan-based conditioning regimen, unmanip-
ulated PBSC allograft, and PT/Cy, tacrolimus, and MMF [9]. In
addition to intensiﬁcation of the preparative regimen dose as
a strategy to reduce the risk of recurrence in high-risk ma-
lignancies, we also postulated that the use of PBSC, instead of
BM, as the stem cell source may provide additional beneﬁt in
patients with high-risk malignancies. The use of PBSC,
although associated with a higher incidence of chronic
GVHD, has also been correlated with a signiﬁcantly
decreased risk of relapse in several large meta-analyses [20-
22]. In our previous study, we provided transplantation to 20
patients with high-risk hematologic malignancies, including
11 (55%) who were not in remission at the time of trans-
plantation. All patients had durable engraftment, with low
rates of treatment-relatedmortality (10%). The 1-year OS and
DFS were respectable at 69% and 50%, respectively, for all
patients; and 88% and 67%, respectively, when considering
only patients who underwent transplantation in remission.
Table 2
Comparison of Haplo and MUD Transplantation Recipient Characteristics
Characteristic Haplo (n ¼ 30) MUD (n ¼ 48) MUD-PBSC (n ¼ 32) P Value (MUD
versus Haplo)
P Value (MUD-PBSC
versus Haplo)
Age, median (min, max) 46 (24, 60) 45 (19, 69) 44 (19, 67) .805 .549
Gender .639 1.000
Female 16 (53%) 29 (60%) 18 (56%)
Male 14 (47%) 19 (40%) 14 (44%)
Diagnosis .509 .896
ALL 6 (20%) 11 (23%) 7 (22%)
AML 16 (53%) 21 (43%) 15 (47%)
CLL 0 (0%) 1 (2%) 1 (3%)
CML 5 (17%) 7 (15%) 5 (16%)
MDS 1 (3%) 7 (15%) 3 (9%)
NHL 2 (7%) 1 (2%) 1 (3%)
Transplantation status
CR/CP 22 (73%) 35 (73%) 23 (72%)
Advanced disease 8 (27%) 13 (27%) 9 (28%)
Disease risk (DFDRI) .091 .298
Low/intermediate 16 (53%) 35 (73%) 22 (69%)
High/very high 14 (47%) 13 (27%) 10 (31%)
HCT-CI .400 .156
0 7 (23%) 17 (35%) 15 (47%)
1/2 13 (43%) 14 (30%) 10 (31%)
3 10 (33%) 17 (35%) 7 (22%)
CMV serostatus .135 .141
DþRþ 17 (57%) 15 (31%) 10 (31%)
DRþ 4 (13%) 12 (25%) 9 (28%)
DþR 4 (13%) 6 (13%) 3 (10%)
DR 5 (17%) 15 (31%) 10 (31%)
Stem cell source <.001 1.00
PBSC 30 (100%) 32 (67%) 32 (100%)
BM 0 (0%) 16 (33%) 0 (0%)
Preparative regimen
TBI/Cy (þFlu - Haplo) 30 (100%) 4 (8%) 3 (9%) <.001 <.001
TBI/VP16 0 (0%) 10 (21%) 7 (22%)
Bu/Cy 0 (0%) 31 (65%) 21 (66%)
Flu/Bu4 0 (0%) 3 (6%) 1 (3%)
GVHD prophylaxis
Tac/Mtx 0 (0%) 48 (100%) 32 (100%) <.001 <.001
PTCy/Tac/MMF 30 (100%) 0 (0%) 0 (0%)
HLA match (MUD)
10/10 N/A 45 (94%) 30 (94%)
9/10 (DQ mm) N/A 3 (6%) 2 (6%)
Transplantation period May 2011-May 2014 Jan 2010-Dec 2013 Jan 2010-Oct 2013
Data presented are n (%), unless otherwise speciﬁed.
D indicates donor; R, recipient; Flu, ﬂudarabine; VP16, etoposide; Bu, busulfan; Tac, tacrolimus; Mtx, methotrexate; N/A, not available; DQ mm, HLA-DQ
mismatch.
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were 10% and 35%, respectively, which appear lower than our
current experience with TBI-based myeloablative haplo-
HSCT. A relationship between TBI-based myeloablative con-
ditioning with increased acute [23,24] and chronic [23]
GVHD has been reported in the setting of PBSC trans-
plantation, in contrast to the lack of effect in the setting of
marrow transplantation [25,26].
Several other groups have published similar experiences
with myeloablative haplo-HSCT with PT/Cy. Grosso et al. [7]
reported a “2-step” strategy where a deﬁned dose of hap-
loidentical T cells (2  108/kg) were infused after myeloa-
blative doses of TBI. Patients then received 60 mg/kg of CYon
2 consecutive days, followed later by infusion of highly pu-
riﬁed CD34þ cells from the donor. All patients engrafted and
the cumulative incidences of grade III and IV acute GVHD and
NRM were 7.4% and 22.5%, respectively, for the 27 patients
treated. With a median follow-up of 40 months, OS was 48%.
A second study from the same group [27], which includes
only patients in remission at the time of transplantation,
demonstrated a 2-yr NRM, relapse, and progression-free
survival (PFS) of 4%, 19% and 74%, respectively (which com-
pares similarly to those seen in our studyd3%, 24%, and 73%,respectively). Raiola et al. [8] reported on 50 patients
receiving a myeloablative haplo-HCT, a BM graft, and PT/CY.
The regimens used were thiotepa, busulfan, and ﬂudarabine
(n ¼ 35) or TBI and ﬂudarabine (n ¼ 15). Forty-ﬁve patients
(90%) engrafted with an 18-month cumulative incidence of
NRM, relapse, and PFS of 18%, 22%, and 51%, respectively. PFS
was 67% for patients who underwent transplantation in
remission versus 37% for patients who underwent trans-
plantation with active disease.
When comparing our results with TBI-based myeloa-
blative haplo-HSCT with the other 2 published experiences
referenced above, it becomes evident that disease risk, as
deﬁned by either the DRI or disease status at the time of
transplantation, is the primary driver of outcomes. The role
of preparative regimen intensity is more difﬁcult to deﬁne,
although relapse rates in all 3 studies (19% to 24%) appears
lower than reported for NMA haplo bone marrow trans-
plantation (BMT) (45% to 51%) [5,6]. Whether PBSC or BM is
the preferred stem cell source after myeloablative
haplo-HSCT remains unclear; however, BM appears to be
associated with a higher rate of graft failure, occurring in
approximately 10% of patients in both the series by Raiola
et al. [8] as well as the experience of Symons et al., recently
Figure 4. Kaplan-Meier analysis of disease-free survival, comparing recipients
of myeloablative haplo-HSCT versus myeloablative MUD transplants for (A) all
patients, (B) patients with low/intermediate disease risk, and (C) patients with
high/very high disease risk.
Figure 5. Cumulative incidence of (A) grade II to IV acute GVHD, and (B)
moderate-to-severe chronic GVHD, comparing recipients of myeloablative
haplo-HSCT versus myeloablative MUD transplantation.
Table 3
Comparison of Haplo and MUD Transplantation Outcomes
Outcome Haplo
(n ¼ 30)
MUD
(n ¼ 48)
MUD-PBSC
(n ¼ 32)
P Value
(MUD
versus
Haplo)
P Value
(MUD-PBSC
versus Haplo)
Acute GVHD 2-4 43% 63% 63% .049 .069
Acute GVHD 3-4 23% 23% 31% .929 .377
Chronic GVHD 56% 69% 69% .315 .242
Mild 34% 11% 5%
Moderate 12% 35% 39%
Severe 10% 23% 25%
NRM (2 yr) 3% 13% 16% .196 .130
Low risk 0% 6% 9% .344 .247
High risk 8% 31% 30% .162 0.181
Relapse (2 yr) 24% 23% 28% .917 .725
Low risk 0% 20% 23% .057 .044
High risk 53% 32% 40% .224 .454
DFS (2 yr) 73% 64% 56% .502 .216
Low risk 100% 74% 68% .032 .017
High risk 39% 37% 30% .821 .858
OS (2 yr) 78% 71% 62% .550 .185
Low risk 100% 78% 67% .062 .019
High risk 52% 54% 50% .926 .768
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Tandem Meetings [28]. Graft failure has not been reported
with PBSC based myeloablative haplo-HSCT and PT/Cy.
Our study has much in common with the “2-step” strat-
egy by Grosso et al., utilizing TBI-based myeloablative con-
ditioning, PBSC as the stem cell source, and PT/Cy,
tacrolimus, and MMF for GVHD prophylaxis. Both report
similar safety proﬁles with universal engraftment, low rates
of infectious complications, low rates of NRM (3% versus 4%),
and favorable 2-yr survival (78% versus 77%). The rates of
grade III and IV GVHD and total chronic GVHD appear higher
in our report (23% versus 4%, and 56% versus 22%), although
chronic GVHD rates are naturally difﬁcult to compare
between different institutions because of differences inlong-term GVHD surveillance practices. The majority of
chronic GVHD in our study was mild (10 of 16 cases) by
National Institutes of Health criteria (1 or 2 organs with a
severity score of 1, indicating no signiﬁcant impairment of
function or activities of daily living). It is noteworthy that
severe chronic GVHD (10% versus 8%) was similar between
S.R. Solomon et al. / Biol Blood Marrow Transplant 21 (2015) 1299e13071306the 2 protocols, as were OS and NRM. The requirement for
stringent ex vivo T depletion of the hematopoietic cell
product differentiates the “2-step” approach from ours and
may limit its widespread applicability. Furthermore, given
the resistance of hematopoietic stem cells to CY [29], such
delayed infusion of selected CD34þ cells may be unnecessary.
An unexpected outcome of our previous busulfan-based
myeloablative haplo-HSCT experience [9] was a higher-
than-expected rate of BK viruseinduced HC. Although
there was no mortality associated with this complication, it
caused signiﬁcant morbidity in patients. Several prior
retrospective studies have suggested an association of high-
dose busulfan with the development of HC [30-33], partic-
ularly in the setting of HLA-mismatched transplantations,
where HC incidence ranged from 35% to 58% [32,34,35]. TBI,
on the other hand, has been associated with signiﬁcantly less
risk of HC in both retrospective and prospective studies
[25,36]. In light of these ﬁndings, we initiated the current
clinical trial utilizing TBI-based myeloablative conditioning,
instead of busulfan, for haplo-HSCT. In the current study, the
incidence of BK viruseinduced HC was signiﬁcantly lower
than that seen in our prior study (30% versus 75%, P ¼ .005,
respectively, for all HC; 7% versus 30%, P ¼ .037 respectively
for grade  3 HC). We believe that the switch from busulfan
to TBI in the conditioning regimen was the major reason for
this effect, as all other aspects of the regimen (stem cell
source, GVHD prophylaxis, antimicrobial prophylaxis)
remained the same. Clinically signiﬁcant morbidity from BK
virus occurs only with grade 3 HC, which typically requires
hospital admission for pain control and/or bladder irrigation.
This was relatively rare in our study, occurring in 2 cases
(6.6% of 30 patients). As a comparison, Grosso et al. reported
1 case (3.6% of 28 patients), using their “2-step” TBI-based
myeloablative haplo-HSCT [27].
In this report, we further show that survival outcomes
after myeloablative haplo-HSCT are similar to that seen in a
well-matched group of contemporaneously treated patients
receiving myeloablative MUD transplantation. Despite a
trend to higher disease risk among haplo-HSCT recipients
(47% versus 27% high/very high disease risk, P ¼ .091), there
was no statistical difference in the incidence of relapse and
survival. Furthermore, in the subset of patients with low/
intermediate risk disease, 2-yr DFS was superior after haplo
compared with MUD transplantations (100% versus 74%, P ¼
.032). The incidence of grade II to IV acute GVHD (43% versus
63%, P ¼ .049) and moderate-to-severe chronic GVHD (22%
versus 58%, P ¼ .003) was signiﬁcantly lower after hap-
loidentical versus MUD transplantation, leading to a low
NMR (3% versus 13%, haplo-HSCT versus MUD; P ¼ not sig-
niﬁcant). The lower incidence of chronic GVHD occurred
despite the greater use of PBSC in the haplo-HSCT group.
When considering the optimal transplan donor type,
MUD versus haplo-HSCT, one must also consider the
inherent advantages of haplo donors including near univer-
sal and rapid availability, as well as lower costs related to
donor searching and graft acquisition. Whereas as almost all
patients have an available haplo-matched family member,
the availability of an 8/8 matched unrelated donor varies
according to ethnic/racial background, ranging from 75% for
white patients of European descent to less than 20% for black
Americans of all ethnic backgrounds; for Hispanics, Asians,
Paciﬁc Islanders, and Native Americans, availability ranges
from 27% and 52% [1]. Furthermore, given the complexities
inherent in registry searching, time from initiation of donor
searching to transplantation can be signiﬁcant, averagingaround 3 to 4 months [37-39]. Invariably, a proportion of
patients will never proceed to transplantation, either
because an appropriately matched donor cannot be found, or
because disease recurrence or medical complications in the
patient intervene. In 1 such study, about 45% of all patients
for whom an unrelated allograft had been searched ﬁnally
underwent transplantation, due to either lack of donor (20%)
or deterioration of the patient’s condition before donor
identiﬁcation (35%) [40]. Delays in getting patients to
transplantation are adversely associated with patient
outcome [39,41,42]. Therefore, getting patients to trans-
plantation as quickly as feasibly possible should be of para-
mount importance.
Use of unrelated donors has also emerged as a signiﬁcant
cost driver, especially when the costs of stem cell procure-
ment are included [40,43,44]. Total costs, including costs for
donor search and graft acquisition, have been reported to be
50% to 60% higher after MUD versus sibling donor trans-
plantations [40,45]. In the study by van Agthoven et al. [40],
average 2-year costs, including donor identiﬁcation expenses
per patient undergoing transplantation (in Euros), were
V98,334 (sibling bone marrow transplantation), V98,977
(sibling PBSC transplantation), and V151,754 (MUD), repre-
senting a 53% increase in costs for unrelated donor versus
sibling donor transplantation. Nearly one third of the costs
for MUD transplantationwas spent on the search for a donor.
When considering haplo-HSCT, costs for donor searching and
stem cell procurement should be comparable to sibling
donor transplantation, except for the extra HLA typing costs
of additional family members. Therefore, from a macroeco-
nomic perspective, we speculate that there should be
signiﬁcant cost saving from a strategy that prioritizes haplo-
HSCT over MUD transplantation.
In conclusion, our results show that myeloablative haplo-
HSCT using this TBI-based regimen results in favorable
engraftment (100%), lowNRM (3%), and an acceptable relapse
rate (24%), similar to that expected after myeloablative MUD
transplantation. Two-year DFS is not different from that seen
in contemporaneous recipients of MUD transplants, although
there appears to be improved DFS in haplo-HSCT patients
with standard-risk disease. Haplo-HSCT may provide a
beneﬁt over MUD transplantation because of (1) increased
donor availability, particularly in non-Caucasian patients; (2)
more rapid access to donors, which may avoid unnecessary
transplantation delays; and (3) lower donor searching and
graft acquisition costs. Myeloablative haplo-HSCT is a valid
option for patients with advanced hematologic malignancies
who lack timely access to a conventional donor.
ACKNOWLEDGMENTS
Financial disclosure: The authors have nothing to disclose.
Conﬂict of Interest Statement: There are no conﬂicts of
interest to report.
Authorship contributions: S.R.S. designed the study; S.R.S,
L.E.M, H.K.H, and A.B. performed the research; S.B., C.A.S, and
M.S. collected the data; C.A.S., S.R.S, and X.Z. analyzed and
interpreted the data; S.R.S. drafted the manuscript; and S.R.S,
C.A.S., M.S., X.Z., S.B., L.E.M., H.K.H., and A.B. critically
reviewed the manuscript. All authors approved the
manuscript.
REFERENCES
1. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for he-
matopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371:
339-348.
S.R. Solomon et al. / Biol Blood Marrow Transplant 21 (2015) 1299e1307 13072. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from
related donors other than HLA-identical siblings. N Engl J Med. 1985;
313:765-771.
3. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow
transplants for leukemia using donors other than HLA-identical sib-
lings. J Clin Oncol. 1997;15:1767-1777.
4. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched he-
matopoietic stem-cell transplantation: a phase II study in patients with
acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:3447-3454.
5. Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone
marrow transplantation for hematologic malignancies using non-
myeloablative conditioning and high-dose, posttransplantation cyclo-
phosphamide. Biol Blood Marrow Transplant. 2008;14:641-650.
6. Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor trans-
plantation after reduced intensity conditioning: results of parallel
phase 2 trials using partially HLA-mismatched related bone marrow or
unrelated double umbilical cord blood grafts. Blood. 2011;118:282-288.
7. Grosso D, Carabasi M, Filicko-O’Hara J, et al. A 2-step approach to
myeloablative haploidentical stem cell transplantation: a phase 1/2
trial performed with optimized T-cell dosing. Blood. 2011;118:
4732-4739.
8. Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical
bone marrow transplantation and posttransplantation cyclophospha-
mide for hematologic malignancies after myeloablative conditioning.
Biol Blood Marrow Transplant. 2013;19:117-122.
9. Solomon SR, Sizemore CA, Sanacore M, et al. Haploidentical trans-
plantation using T cell replete peripheral blood stem cells and mye-
loablative conditioning in patients with high-risk hematologic
malignancies who lack conventional donors is well tolerated and
produces excellent relapse-free survival: results of a prospective phase
II trial. Biol Blood Marrow Transplant. 2012;18:1859-1866.
10. Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte
colony-stimulating factor-mobilized peripheral blood mononuclear
cell grafts affects engraftment kinetics and development of extensive
chronic graft-versus-host disease after human leukocyte antigen-
identical sibling transplantation. Blood. 2001;98:3221-3227.
11. Mohty M, Bilger K, Jourdan E, et al. Higher doses of CD34þ peripheral
blood stem cells are associated with increased mortality from chronic
graft-versus-host disease after allogeneic HLA-identical sibling trans-
plantation. Leukemia. 2003;17:869-875.
12. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference
on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
13. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health
consensus development project on criteria for clinical trials in chronic
graft-versus-host disease: I. Diagnosis and Staging Working Group
Report. Biol Blood Marrow Transplant. 2005;11:945-956.
14. Armand P, Kim HT, Logan BR, et al. Validation and reﬁnement of the
Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;
123:3664-3671.
15. O’Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow
transplantation from partially HLA-mismatched related donors using
posttransplantation cyclophosphamide. Biol Blood Marrow Transplant.
2002;8:377-386.
16. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of
reduced intensity and myeloablative conditioning regimen in HLA
identical sibling allogeneic haematopoietic stem cell transplantation
for patients older than 50 years of age with acute myeloblastic
leukaemia: a retrospective survey from the Acute Leukemia Working
Party (ALWP) of the European group for Blood and Marrow Trans-
plantation (EBMT). Leukemia. 2005;19:2304-2312.
17. Mohty M, Labopin M, Volin L, et al. Reduced-intensity versus conven-
tional myeloablative conditioning allogeneic stem cell transplantation
for patients with acute lymphoblastic leukemia: a retrospective study
from the European Group for Blood and Marrow Transplantation.
Blood. 2010;116:4439-4443.
18. Ringdén O, Labopin M, Ehninger G, et al. Reduced intensity condi-
tioning compared with myeloablative conditioning using unrelated
donor transplants in patients with acute myeloid leukemia. J Clin Oncol.
2009;27:4570-4577.
19. Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic
stem-cell transplantation in AML and MDS using myeloablative versus
reduced-intensity conditioning: the role of dose intensity. Leukemia.
2006;20:322-328.
20. Zhang H, Chen J, Que W. Allogeneic peripheral blood stem cell and
bone marrow transplantation for hematologic malignancies: meta-
analysis of randomized controlled trials. Leuk Res. 2012;36:431-437.
21. Stem Cell Trialists’ Collaborative Group. Allogeneic peripheral blood
stem-cell compared with bone marrow transplantation in the man-
agement of hematologic malignancies: an individual patient data meta-
analysis of nine randomized trials. J Clin Oncol. 2005;23:5074-5087.
22. Chang YJ, Weng CL, Sun LX, Zhao YT. Allogeneic bone marrow trans-
plantation compared to peripheral blood stem cell transplantation for
the treatment of hematologic malignancies: a meta-analysis based on
time-to-event data from randomized controlled trials. Ann Hematol.
2012;91:427-437.23. Nagler A, Rocha V, Labopin M, et al. Allogeneic hematopoietic stem-cell
transplantation for acute myeloid leukemia in remission: comparison
of intravenous busulfan plus cyclophosphamide (Cy) versus total-body
irradiation plus Cy as conditioning regimenea report from the acute
leukemia working party of the European group for blood and marrow
transplantation. J Clin Oncol. 2013;31:3549-3556.
24. Copelan EA, Hamilton BK, Avalos B, et al. Better leukemia-free and
overall survival in AML in ﬁrst remission following cyclophosphamide
in combination with busulfan compared with TBI. Blood. 2013;122:
3863-3870.
25. Ringden O, Remberger M, Ruutu T, et al. Increased risk of chronic graft-
versus-host disease, obstructive bronchiolitis, and alopecia with
busulfan versus total body irradiation: long-term results of a ran-
domized trial in allogeneic marrow recipients with leukemia. Nordic
Bone Marrow Transplantation Group. Blood. 1999;93:2196-2201.
26. Litzow MR, Perez WS, Klein JP, et al. Comparison of outcome following
allogeneic bone marrow transplantation with cyclophosphamide-total
body irradiation versus busulphan-cyclophosphamide conditioning
regimens for acute myelogenous leukaemia in ﬁrst remission. Br J
Haematol. 2002;119:1115-1124.
27. Grosso D, Gaballa S, Alpdogan O, et al. A two-step approach to mye-
loablative haploidentical transplantation: low nonrelapse mortality
and high survival conﬁrmed in patients with earlier stage disease. Biol
Blood Marrow Transplant. 2015;21:646-652.
28. Symons HJ, Chen A, Gamper C, et al. Haploidentical BMT using fully
myeloablative conditioning, T cell replete bone marrow grafts, and
post-transplant cyclophosphamide (PT/Cy) has limited toxicity and
promising efﬁcacy in largest reported experience with high risk he-
matologic malignancies. Biol Blood Marrow Transplant. 2015;21:S29.
29. Kastan M, Schlaffer E, Russo J, et al. Direct demonstration of elevated
aldehyde dehydrogenase in human hematopoietic progenitor cells.
Blood. 1990;75:1947-1950.
30. Yaghobi R, Ramzi M, Dehghani S. The role of different risk factors in
clinical presentation of hemorrhagic cystitis in hematopoietic stem cell
transplant recipients. Transplant Proc. 2009;41:2900-2902.
31. Trotman J, Nivison-Smith I, Dodds A. Haemorrhagic cystitis: incidence
and risk factors in a transplant population using hyperhydration. Bone
Marrow Transplant. 1999;23:797-801.
32. Silva Lde P, Patah PA, Saliba RM, et al. Hemorrhagic cystitis after allo-
geneic hematopoietic stem cell transplants is the complex result of BK
virus infection, preparative regimen intensity and donor type. Hae-
matologica. 2010;95:1183-1190.
33. Seber A, Shu XO, Defor T, et al. Risk factors for severe hemorrhagic
cystitis following BMT. Bone Marrow Transplant. 1999;23:35-40.
34. Ogawa H, Ikegame K, Yoshihara S, et al. Unmanipulated HLA 2-3
antigen-mismatched (haploidentical) stem cell transplantation using
nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2006;
12:1073-1084.
35. Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte
globulin followed by unmanipulated HLA-mismatched/haploidentical
blood and marrow transplantation can achieve comparable outcomes
with HLA-identical sibling transplantation. Blood. 2006;107:3065-3073.
36. Kroger N, Zabelina T, Kruger W, et al. Comparison of total body irra-
diation vs busulfan in combination with cyclophosphamide as condi-
tioning for unrelated stem cell transplantation in CML patients. Bone
Marrow Transplant. 2001;27:349-354.
37. Tiercy JM. Unrelated hematopoietic stem cell donor matching proba-
bility and search algorithm. Bone Marrow Res. 2012;2012:695018.
38. Rambaldi A, Bacigalupo A, Fanin R, et al. Outcome of patients activating
an unrelated donor search: the impact of transplant with reduced in-
tensity conditioning in a large cohort of consecutive high-risk patients.
Leukemia. 2012;26:1779-1785.
39. Heemskerk MB, van Walraven SM, Cornelissen JJ, et al. How to improve
the search for an unrelated haematopoietic stem cell donor. Faster is
better than more!. Bone Marrow Transplant. 2005;35:645-652.
40. van Agthoven M, Groot MT, Verdonck LF, et al. Cost analysis of HLA-
identical sibling and voluntary unrelated allogeneic bone marrow
and peripheral blood stem cell transplantation in adults with acute
myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow
Transplant. 2002;30:243-251.
41. Frassoni F, Labopin M, Powles R, et al. Effect of centre on outcome of
bone-marrow transplantation for acute myeloid leukaemia. Acute
Leukaemia Working Party of the European Group for Blood and
Marrow Transplantation. Lancet. 2000;355:1393-1398.
42. Craddock C, Labopin M, Pillai S, et al. Factors predicting outcome after
unrelated donor stem cell transplantation in primary refractory acute
myeloid leukaemia. Leukemia. 2011;25:808-813.
43. Saito AM, Cutler C, Zahrieh D, et al. Costs of allogeneic hematopoietic
cell transplantation with high-dose regimens. Biol Blood Marrow
Transplant. 2008;14:197-207.
44. Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell trans-
plantation. Blood. 2012;120:1545-1551.
45. Matthes-Martin S, Potschger U, Barr R, et al. Costs and cost-
effectiveness of allogeneic stem cell transplantation in children are
predictable. Biol Blood Marrow Transplant. 2012;18:1533-1539.
